Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd

Caitong International Asset Management Co. Ltd raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1,116,754.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 122,854 shares of the biopharmaceutical company’s stock after buying an additional 122,843 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Ultragenyx Pharmaceutical were worth $2,826,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of RARE. Assetmark Inc. boosted its position in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,024 shares in the last quarter. Huntington National Bank increased its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $56,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 43.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 751 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares in the company, valued at $702,129.12. The trade was a 17.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares in the company, valued at $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 24,002 shares of company stock worth $575,039. Company insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $27.44 on Friday. The stock’s 50 day moving average price is $24.34 and its 200 day moving average price is $24.88. The firm has a market capitalization of $2.70 billion, a PE ratio of -4.49 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a one year low of $18.29 and a one year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter last year, the firm posted ($1.57) EPS. The firm’s quarterly revenue was down 2.2% on a year-over-year basis. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their price target for the company from $61.00 to $25.00 in a report on Tuesday, March 24th. Truist Financial upgraded Ultragenyx Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Morgan Stanley lifted their price objective on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. Finally, JPMorgan Chase & Co. dropped their target price on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $59.56.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.